and, to a lesser extent, other serine proteases such as trypsin and plasmin. A scrambled TRAP, proteolytitally inactive PPACK-thrombin, DIP-thrombin, and type IV collagenase were ineffective. Together, these results suggest that the thrombin effects are m .ediated by proteolytic activation of the throm bin receptor. Possible involvement of the phospholipase C-signaling pathway in thrombin-mediated ECM protein deposition was also investigated. Inhibition or downregulation of protein kinase C (PKC) and chelation of intracellular or extracellular Ca2+ did not suppress, but rather enhanced, basal and thrombin-stimulated ECM protein deposition. Quantitative differences in augmentation of basolateral deposition by these treatments suggest differential regulatory pathways for individual ECM proteins. Our data indicate that, in cultured RAMEC, short-term activation of the thrombin receptor causes an increase in amounts of deposited ECM protein by a cellular signaling pathway that is independent of PKC activation and/or elevation of intracellular Ca2+.
Thrombin, through as yet unidentified mechanisms, promotes in vivo angiogenesis and incisional wound healing (4, 39) . Both of these processes involve EC activation and remodeling of the subendothelial extracellular matrix (ECM). ECM remodeling can occur either at the beginning of the angiogenic process by degradation of the basement membrane or at the end by de novo synthesis and deposition of basement membrane proteins (22) . We hypothesize that thrombin's angiogenic properties might, in part, be due to its capacity to initiate ECM remodeling. Indeed, previous studies have shown that long-term incubation of EC with thrombin causes a modification in the adhesive properties of the ECM (6), a decrease in its collagen content (13), and also an augmentation of the amount of some ECM proteins found in the culture medium, molecule in hemostasis by initiating the formation of blood clots (9). In addition, thrombin possesses ubiquitous bioregulatory functions and elicits a wide range of cellular responses in numerous cell types, including endothelial cells (EC; Ref. 14) . EC responses to thrombin activation include migration, cell shape changes and disruption of EC barrier function, upregulation of cell adhesion molecules, and synthesis and release of vasoactive compounds, thrombomodulatory agents, and fibrinolytic and matrix-degrading enzymes (12).
The molecular mechanisms by which thrombin elicits such a vast array of cellular responses are complex and involve binding to several low-or high-affinity binding sites, including thrombomodulin, as well as activation of the G protein-coupled thrombin receptor (31). The mechanism of activation of this recently cloned receptor involves the proteolytic cleavage of its NH2 terminus by thrombin and subsequent insertion of the tethered receptor ligand into an as yet unknown binding site on the plasma membrane (5). In EC, proteolytic cleavage of the thrombin receptor activates phospholipase C, which in turn catalyzes the production of inositol phosphates and diacylglycerol from phosphatidylinositols (38). Inositol 1,4,5-trisphosphate (IP3) mobilizes the release of Ca2+ from internal stores and also contributes to the entry of extracellular Ca2+, whereas diacylglycerol activates protein kinase C (PKC). In addition, thrombin activates other protein kinases, such as tyrosine phosphokinases (28).
rat; fibronectin; laminin; collagen IV, collagen I THROMBIN,A SERINE PROTEASE generated from its blood-presumably due to a loss of these proteins from the circulating zymogen precursor, prothrombin, is a key subendothelial ECM (11). In addition, thrombin might (1, 16, 24) . A common characteristic of the above studies is the prolonged exposure of the cells to thrombin (hours to days), a condition that is unlikely to occur in vivo in which circulating thrombin is rapidly inactivated and/or removed from the circulation (8). Because thrombin activates both early (phospholipase C activation, permeability, and so forth) and late (protein synthesis, proliferation) events, we rationalized that early effects of thrombin stimulation on ECM protein secretion might differ from some of its previously described long-term effects on ECM remodeling.
To test our hypothesis, we assessed the effects of thrombin on ECM protein secretion from microvascular EC isolated from the rat adrenal medulla (RAMEC). We previously reported the time course for the constitutive secretion of ECM proteins from these cells (30) CeZZ culture. RAMEC were isolated and characterized as previously described (30). The cells were routinely subcultured in DMEM supplemented with 7% fetal calf serum and 7% horse serum, 2.5 mM L-glutamine, 100 pg/ml streptomycin, and 100 U/ml penicillin.
All experiments were performed with postconfluent monolayers of RAMEC from passages 11 through 22. No passage-dependent differences were found in any of the results obtained. Unless stated otherwise, stimulation with thrombin and the subsequent incubations (up to 3 h) were carried out in serum-free medium.
Enzyme-linked immunosorbent assay. Ten thousand RAMEC were plated in each well of 96-well tissue culture plates. One day after reaching confluence, the cells were washed twice with serum-free medium and then stimulated with bovine cx-thrombin or TRAP for 5 min in serum-free medium. Subsequently, they were washed twice and further incubated for 3 h in fresh serum-free medium. At the end of the incubation period, the medium was removed and stored at -80°C. To quantitate the ECM proteins deposited into the subendothelial ECM, the cells were removed from the plates by incubation (10 min) with 20 mM NH*OH at room temperature, as previously described (26). This method has been shown to completely remove the cells and leave an intact ECM attached to the wells (40). After cells were removed, the wells were washed three times with phosphate-buffered saline (PBS; pH 7.4) and incubated with blocking agent (1% bovine serum albumin in PBS, pH 7.4) for 2 h at room temperature.
The levels of basolaterally deposited fibronectin, laminin, collagen IV, and collagen I were measured with an enzyme linked immunosorbent assay (ELISA) that was previously described in detail (30).
The following antibodies were used: 1) Foster City, CA; data not shown). Ratspecific primers 5'-AAGGAGAGACTGGACCATT-3' (sense) and 5'-TGGACAGCCAGTAGGAGTA-3' (antisense) were designed just internal to the mouse primers from the obtained rat sequence. Hybrid primers 5'-AAGGAGAGACTGGACCA-TTCAAGTTTCGTGAGCTGATTG-3' (sense) and 5'-TGGA-CAGCCAGAGGAGTATTGAGTCCATGGGGAGCTTT-3' (antisense) were then generated, containing rat collagen type IV primer sequences joined to v-erb B sequences (underlined) of the PCR MIMIC kit template. This template was amplified with the hybrid primers, and this product was cloned to generate the rat-specific collagen type IV internal standard. Involvement of PKC and Ca2+. PKC was either directly inhibited by incubation of the cells with 10 uM H-7 for 30 min or downregulated by overnight incubation with a high concentration (10 ug/ml) of PMA (37). These treatments were, respectively, >95 and >99% effective in inhibiting and/or downregulating PKC activity, as determined by using a commercial, nonradioactive PKC assay (MESACUP from Medical and Biological Laboratories, Watertown, MA) according to the manufacturer's instruction (data not shown). Extracellular Ca2+ was chelated by incubating the cells for 5 min with either 10 uM EDTA or IO pM BAPTA in Ca2+-free PBS (pH 7.4). Because Ca 2+-free PBS nominally contains < 10 uM Ca2+, we established in preliminary studies that, under these conditions, chelation of extracellular Ca2+ did not cause detachment of the monolayer. Intracellular Ca2+ was chelated by incubating the cells for 1 h with 25 uM of permeant BAPTA-AM (7). Intracellular Ca2+ was elevated by incubation of the cells with the Ca2+ ionophore A-23187 (10 pM) for 15 min. After these treatments, the cells were stimulated for 5 min with 0.25 U/ml thrombin and further processed as described above. Cell viability was not affected by any of these treatments.
StatisticaL analysis. 
RESULTS
Thrombin stimulates basolateral ECM protein deposition. l Postconfluent monolayers of RAMEC were stimulated for 5 min with 0.025 U/ml thrombin in serum-free medium and subsequently incubated in fresh serum-free medium for l-6 h. The amounts of basolaterally deposited ECM proteins (fibronectin and laminin) were significantly increased in thrombinstimulated cells, whereas they remained virtually unchanged in the unstimulated controls (Fig. 1) . Qualitatively similar results were obtained for collagen types I and IV (data not shown). For all ECM proteins studied, a significant increase in basolateral deposition could be reliably measured -1 h after the initial 5-min stimulation with thrombin, reaching a plateau at 3 h.
We also tested the effects of varying the length of thrombin stimulation on ECM protein deposition. As exemplified in Fig. 2 for fibronectin, maximal stimulation was obtained after a 5-min exposure to thrombin. Prolonged incubation of the cells with thrombin for >30 min resulted in a decline in the amount of basolaterally deposited fibronectin. If the cells were stimulated for 1 l Throughout this paper, for the sake of simplicity, the basolateral secretion of ECM proteins into the subendothelial cell space and incorporation into a nonextractable ECM has been termed "deposition." The apical secretion of ECM proteins into the luminal space (cell culture medium) has been termed "release."
The term "secretion" refers to the phenomenon of (polarized) discharge of ECM proteins. thrombin induced a bell-shaped augmentation of the amounts of basolaterally deposited ECM proteins (Fig.  3) . A significant dose-dependent increase was observed at concentrations of thrombin between 0.005 and 0.25 U/ml. The 50% effective concentration (EC& values for this stimulatory effect were 0.025, 0.032, 0.06, and 0.083 U/ml for fibronectin, laminin, collagen type IV, and collagen type I, respectively. Although the levels deposited under basal conditions varied significantly among the individual ECM proteins (from 7.5 rig/well for collagen type I up to 120 rig/well for collagen type IV), maximal stimulation (at 0.25 U/ml thrombin) amounted to up to a three-to fourfold increase over basal values for all four ECM proteins. This stimulatory effect decreased gradually at higher thrombin concentrations. For example, at 2 U/ml of thrombin, the deposited levels of all ECM proteins were essentially identical to the unstimulated levels. At even higher thrombin concentrations, the "deposited" amounts of the ECM proteins decreased to below basal levels (not shown), presumably due to a partial dissolution of the subendothelial ECM (11). This finding confirms and extends previous studies in which prolonged (X h) 25 Thrombin (U/ml) incubation of EC monolayers with high levels of thrombin resulted in the release of ECM proteins from the subendothelial matrix into the culture medium (6, 24). Inclusion of serum in the incubation medium during and after the 5min stimulation with thrombin abrogated the increase in ECM protein deposition at thrombin concentrations up to 0.25 U/ml (data not shown).
Thrombin attenuates apical ECM protein release. In addition to quantitating basolateral deposition, we also measured, in the same experiments, the apical release of fibronectin, laminin, and collagen IV into the cell culture medium by using an inhibition ELISA. In contrast to the increase in basolateral ECM protein deposition described above, the same treatment resulted in a qualitatively opposite, bell-shaped decrease in apical ECM protein release (Fig. 3) . At low concentrations of thrombin (co.25 U/ml), apical ECM protein release was significantly reduced in a dose-dependent fashion (up to a three-to fourfold decline from basal levels). At higher concentrations, the inhibitory action of thrombin gradually decreased. It is noteworthy that the EC& values and the maximally effective thrombin concentration for both the release and the deposition of each ECM protein were essentially identical.
The results presented so far suggest that I) shortterm stimulation of RAMEC with low concentrations of thrombin results in an enhanced basolateral deposition of ECM proteins and 2) ECM protein release and deposition appear to be reciprocally interrelated.
Thrombin-induced ECM protein deposition does not require de novo mRNA or protein synthesis.
?Lvo independent sets of experiments were carried out to determine whether, during the time course of our experiments, thrombin-stimulated ECM protein deposition requires de novo mRNA or protein synthesis.
First, as detailed in MATERIALS AND METHODS, we designed a quantitative RT-PCR assay to assess the effects of thrombin stimulation on steady-state mRNA levels in RAMEC. As seen in Fig. 4 , the steady-state mRNA levels for collagen IV were not detectably affected by treatment of RAMEC with 0.25 U/ml of thrombin for 5 min and subsequent incubation for another 3 h. Similar results were obtained with fibronectin (data not shown).
Second, inhibition of de novo mRNA or protein synthesis with, respectively, 10 pM actinomycin D or 10 yg/ml cycloheximide did not inhibit the stimulatory effect of thrombin on ECM protein deposition (Table 1) . On the contrary, in the presence of these two ubiquitous inhibitors, thrombin-induced ECM protein deposition was significantly augmented presumably because these compounds indiscriminately inhibit de novo synthesis of all mRNAand cellular proteins, including those that might affect ECM protein secretion. During the time course of this experiment (3 h), stimulation with thrombin did not cause an overall increase in the amount of total protein contents per well, as measured with the Bradford assay (not shown).
We Previous studies have shown that prolonged (1 h) stimulation of human umbilical vein EC and bovine aortic EC with thrombin causes a time-and/or dosedependent loss of ECM molecules from the subendothelial matrix (11, 24). We investigated whether a similar phenomenon occurs in RAMEC. In contrast to our standard (5-min stimulation) protocol, we stimulated the cells with increasing concentrations of thrombin for 1 h and measured the amounts of fibronectin, laminin, collagen IV, and collagen I in the ECM and in the culture medium 2 h later. As seen in Fig. 5 , the amounts of these four proteins in the ECM were decreased in a dose-dependent fashion, whereas the amounts released into the culture medium were increased, correspond- protein secretion. To confirm this notion, we stimulated Stimulation of ECM protein deposition by other ser-1 RAMEC with y-thrombin, which is proteolytically ac-ineproteases. Recent studies suggest that the thrombin tive but lacks the anion-binding site (lo), as well as receptor can be proteolytically activated also by other with two proteolytically inactive analogs of human serine proteases, notably trypsin and plasmin (41). To ol-thrombin, PPACK-cx-thrombin and DIP-oc-thrombin.
test whether other proteases can mimic the effects of As expected, y-thrombin enhanced ECM deposition to a thrombin on ECM protein deposition, we exposed similar degree as cx-thrombin, whereas both proteolyti-RAMEC under similar experimental conditions (e.g., tally inactive analogs were without effect. These re-similar proteolytic activities, same duration, and so sults clearly establish that thrombin mediated ECM forth) to the serine proteases trypsin and plasmin and protein deposition requires proteolytic activation of the to the metalloprotease collagenase type IV. Exposure thrombin receptor.
for 5 min to 0.25 U/ml trypsin and plasmin stimulated the deposition of the ECM proteins studied, albeit to a lesser extent than thrombin (Table 3 ). In contrast, type IV collagenase did not stimulate ECM protein secretion. Thus it appears that proteolytic activation of the thrombin receptor by other serine proteases is sufficient for stimulation of ECM protein deposition.
lated ECMprotein deposition. Two of the best-characterized signal transduction pathways involved in thrombin-PKC and Ca2+ are not involved in thrombin-stimurespectively, resulted in an increase in the levels of deposited ECM proteins (Table 4) . For example, for type I and type IV collagen, inhibition and/or downregulation of PKC resulted in an increase in the basolateral deposition approximately equivalent to that observed with thrombin. PKC inhibition and/or downregulation did not further augment the stimulatory effect of thrombin on collagen type I and collagen type IV deposition. Short-term PKC inhibition by H-7 significantly augmented the deposition of fibronectin but not of laminin. In contrast, long-term PKC downregulation by PMA increased the deposition of laminin and, to a much lesser extent, of fibronectin. Moreover, both H-7 and PMA treatments augmented the thrombin-induced increase in the basolateral deposition of both of these ECM proteins in a fashion reminiscent of the inhibitors' effects on basal secretion. tion of extracellular Ca2+ resulted in stronger enhancement of collagen IV deposition, at approximately two to As seen in Table 5 , chelation of extracellular Ca2+ in either BAPTA-or EDTA-containing Ca2+-free PBS resulted in an increase in the deposited amounts of fibronectin, laminin, and collagen type I to levels similar to the maximum levels induced by thrombin stimulation. Subsequent stimulation with thrombin caused only a marginal, if any, further increase in the deposition of these ECM proteins. In contrast, chelainduced EC activation include elevation of intracellular Ca2+ and (activation of) PKC-mediated protein phosphorylation (12). We evaluated the possible involvement of these signaling pathways in the mechanism of both the basal and the thrombin-stimulated ECM protein deposition in cultured RAMEC with established stimulators and inhibitors. Pretreatment of RAMEC with either H-7 or PMA under conditions that inhibit or downregulate PKC, threefold above the level obtained with thrombin alone.
Depletion of intracellular Ca2+ by preincubation of the cells with cell-permeant BAPTA-AM resulted in an increased deposition of fibronectin, laminin, and collagen type I similar to that observed when extracellular Ca2+ was chelated. Subsequent thrombin stimulation yielded a statistically significant (P < 0.05) elevation in the basolateral deposition of fibronectin and collagen IV above that induced by BAPTA-AM (Table 5) . Again, From these data, we conclude that the effect of thrombin is mediated through neither PKC activation nor an increase in intracellular Ca2+ concentration. Two other interesting observations also emerge from our results: 1) basal ECM protein deposition and release are negatively coupled to the activation of Ca2+ and PKC, and 2) basal and thrombin-induced ECM protein deposition entail distinct signaling mechanisms for the various ECM proteins studied.
DISCUSSION
The main finding of this study is that a brief (5 min) exposure of confluent RAlYIEC cultures to low concentrations of thrombin within the physiological range significantly increased the deposition of fibronectin, laminin, and collagens I and IV into the subendothelial matrix. Concomitantly, the same treatment decreased the release of these proteins into the medium. Previous studies, which examined the effect of thrombin on ECM protein deposition or release by cultured EC, were based on the continuous presence of thrombin for up to 24 h in the culture medium (6, 11, 24) . In those studies, thrombin increased the amounts of fibronectin and collagen released by the cells into the medium, presum ably due to a loss of these proteins from the subendotheha1 matrix. These findings might be explained by the recent observation (43) that long-term stimulation of EC with thrombin induces the expression of matrixdegrading enzymes. In line with those findings, prolonged exposure of RAMEC to thrombin decreased collagen types I and IV, fibronectin, and laminin deposition into the matrix, accompanied by increased release into the medium (Fig. 5) .
To the best of our knowledge, this is the first study to demonstrate the cellular regulation of ECM protein secretion triggered by a short-term (5 min) stimulation by thrombin. Studies on the effects of thrombin after short-term stimulation of cells are physiologically more meaningful than those after long-term stimulation. In vivo, ar-thrombin is either actively incorporated into fibrin clots, rapidly inactivated by various proteinases found in plasma (such as antithrombin III, heparin cofactor II, cx-macroglobulin), or immobilized in the subendothelial basement membrane (8).
Because thrombin-stimulated ECM protein deposition and/or release does not require de nova mRNA or protein synthesis (Fig. 4, Table l) , the most likely explanation for our findings is that short-term exposure of RAMEC to thrombin might activate a polarized, vectorial secretion of these proteins at the basolateral surface of the cells. In the past, EC have been shown to polarize their secretion of certain ECM molecules, such as fibronectin and von Willebrand factor (16, 24) . Alternatively, thrombin might act on cell surface molecules, such as integrins or other receptors responsible for ECM protein assembly, and thus modulate the amounts of molecules deposited into the ECM of the cells.
In addition to this strict time requirement for the observed stimulatory effects of thrombin on ECM protein deposition, our results also reveal a specific, biphasic dose requirement (Fig. 3) . We suggest that thrombin has a dual role in ECM remodeling. In situations in which thrombin is present at low concentrations and for short periods of time (within a narrow "window"), it promotes the deposition of ECM proteins. When thrombin is present for long periods of time and at high concentrations, it causes enhanced loss of proteins from the ECM, presumably by degradation and/or proteolysis.
Two ubiquitous inhibitors of mRNA and protein synthesis, actinomycin D and cycloheximide, respectively, significantly augmented thrombin-stimulated deposition of three of the four ECM proteins studied, most prominently that of collagen type IV (Table 1) . Interestingly, the basal deposition of the various ECM proteins was differentially affected by inhibiting the synthesis of proteins but was not sensitive to inhibition of mRNA transcription: cycloheximide significantly inhibited the basal deposition of fibronectin and collagen type IV without altering the deposited amounts of laminin and collagen type I. Together with our findings that 5-min stimulation of RAMEC with thrombin does not increase the total protein contents, these results provide further support for the notion that thrombin might differentially affect secretory processes rather than stimulating de nova expression of ECM protein genes and gene products.
Regulated secretion is a complex physiological process that involves numerous regulatory cellular and surface proteins (3). Global inhibition of mRNA or protein synthesis might disparately affect the expres sion of some of the proteins that regulate this process and thus might perturb the balance that normally restricts the secretory event. For example, the release of hormones or neurotransmitters is facilitated by removal of the perimembranal web of microfilaments, which are believed to constitute a physical barrier along the plasma membrane (2). Thus we hypothesize that the enhancement of thrombin-mediated deposition of ECM proteins by cycloheximide and actinomycin D might reflect a gradual removal or downregulation of barrier proteins. Indeed, incubation with 10 uM cytochalasin D, a selective disrupter of microfilaments, yielded an enhanced deposition of ECM proteins, comparable with the effects of thrombin in actinomycin-or cycloheximide-treated cells (unpublished observations). In conjunction with data discussed below, the disparate effects of these inhibitors on individual ECM proteins suggest the participation of distinct secretory and/or signaling nathwavs for their stimulated denosition. The stimulatory effects of short-term incubation with thrombin were fully mimicked by a synthetic peptide, TRAP, which represents the new NH2 terminus of the cleaved thrombin receptor and serves as a full agonist of the thrombin receptor (5, 12). These data, together with our results with proteolytically active and inactive thrombin analogs (Table 2) , clearly indicate that the effect of thrombin on ECM protein secretion is mediated through proteolytic activation of the thrombin receptor. Additional evidence is provided by the bellshaped dose dependence of the effects of both thrombin and TRAP, which most likely reflects desensitization due to rapid proteolysis, phosphorylation, or internaliz ation of the thrombin receptor at high concentrations of the agonist (1518).
Another interesting finding of the present study is that two other serine proteases, trypsin and plasmin, affect ECM protein secretion similarly to thrombin (Table 3 
